ArticleAesthetic plastic surgery2026
A Clinical Algorithm for Gynecomastia: From Diagnosis to Surgical Management.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGynecomastia is a heterogeneous disorder spanning the full pediatric-to-adult age range; however, comprehensive single-institution analyses that integrate endocrine, comorbid, drug-related, and surgical perspectives within one framework remain limited. We characterized the demographic and etiologic landscape of gynecomastia in a large retrospective cohort, propose a practical diagnostic algorithm derived from these patterns, and summarize the institutional experience with surgical management.
methodsWe retrospectively reviewed all male patients with an electronic-medical-record diagnosis of gynecomastia at two tertiary academic hospitals between January 2011 and March 2026. True gynecomastia was confirmed clinically and, where indicated, by ultrasonography, mammography, or magnetic resonance imaging. Patients were categorized by primary etiology (physiologic, drug- or substance-induced, endocrine, pathologic systemic, or idiopathic) using a standardized diagnostic workflow, and surgical candidates were graded according to the Simon classification.
resultsOf 754 patients screened, 562 met criteria for true gynecomastia (pediatric ≤ 17 years, 30 [5.3%]; adult ≥18 years, 532 [94.7%]; mean age 58.7 ± 19.8 years; median 64, range 0-95). Bilateral disease accounted for 75.9% of patients with documented laterality. Idiopathic disease was the largest category (362; 64.4%), followed by drug- or substance-induced disease (135; 24.0%), pathologic systemic disease (43; 7.7%; predominantly chronic liver and kidney disease), endocrine disorders (13; 2.3%), and overt physiologic gynecomastia (6; 1.1%). Spironolactone (71 patients; 52.6% of drug-induced cases) and antiandrogen / androgen-deprivation therapy agents (28; 20.7%) jointly accounted for nearly three quarters of drug-induced disease. Etiologic distribution differed markedly by age: physiologic and idiopathic causes predominated in adolescents, whereas drug-induced disease rose sharply from the fifth decade onward and accounted for ≈26-29% of cases in patients aged 50-80 years. Forty-three patients (7.7%) underwent surgical correction (mean age 33.7 ± 18.9 years), most commonly for long-standing persistent disease or cosmetic and psychosocial indications; surgical conversion was substantially higher in idiopathic (9.3%) than in drug-induced (2.2%) or systemic pathologic disease (2.3%). Histopathology confirmed benign glandular hyperplasia in all 43 surgical specimens; no occult male breast carcinoma or other malignant tissue was identified (0 of 43), and patients with male breast carcinoma at initial presentation were excluded a priori.
conclusionsAcross a 15-year cohort, idiopathic and drug-induced disease (chiefly spironolactone and antiandrogen-class agents) accounted for nearly 90% of adult cases. A stepwise algorithm based on examination, medication review, and selective endocrine and radiologic testing classified etiology in routine practice, and surgery matched to Simon grade remained the definitive treatment for long-standing, severe, or psychosocially distressing disease. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42886229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.